6. Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
Price Target Upside: 27.71%
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) specializes in generic and specialty drugs, providing affordable medicines to the U.S. and global markets.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is expanding its presence in the weight loss and metabolic disease sector through a strategic collaboration with Metsera, Inc., announced in October 2024. This partnership positions the company as a key player in the growing obesity treatment market by leveraging Metsera’s innovative drug portfolio and its own manufacturing capabilities.
As part of the agreement, the corporation will serve as Metsera’s preferred supply partner in the U.S. and Europe while gaining commercialization rights in select emerging markets. To support this expansion, Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is investing $150–$200 million over the next four to five years to build two manufacturing facilities in India for peptide synthesis and sterile fill-finish production. The company will also assist in product development, including drug formulation and drug-device innovation.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) and Metsera aim to develop next-generation weight loss therapies, including MET-097, an ultra-long-acting GLP-1 receptor agonist that demonstrated promising Phase 1 trial results, with a 7.5% weight reduction in 36 days. The collaboration also focuses on oral and injectable treatments, including NuSH analogs, designed to address the growing demand for obesity and diabetes therapies.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX)’s expansion into biologics manufacturing strengthens its market position beyond small molecules. In November 2024, the company secured U.S. FDA approval for Exenatide, its first generic GLP-1 injectable, further solidifying its role in the weight loss and diabetes treatment landscape.
Amneal Pharmaceuticals, Inc. (NASDAQ:MRX) reported strong Q3 2024 results with net revenue of $702 million, a 13% increase from last year. Generics revenue grew by 9%, while specialty revenue surged 19%, driven by neurology and endocrinology products. Adjusted EBITDA reached $158 million, up 2%, and adjusted EPS was $0.165. Year-to-date, the company earned $2.68 billion, boosted by strong generics performance, new product launches, and biosimilars. Despite a small GAAP net loss of $0.2 million, the corporation remains focused on high-margin products to enhance profitability.
